The biopharmaceutical industry has made great strides in delivering cost-effective therapies to the market in the shortest timelines within regulatory guidelines. However, these advances are challenged by increasingly complex biologics formats and the subsequent additional analytical work for biologics development. In today’s highly competitive landscape, it is necessary for biotech and pharmaceutical companies to focus on core capabilities while relying on a network of collaborators, vendors and regulatory experts to fill gaps.
Key to biopharmaceutical R&D is selecting contract research organizations (CROs) that share a company’s goals of safety, quality, speed and low cost. At the same time, it is important to evaluate multiple cell line development (CLD) platforms to determine which platform will produce optimal titers.
Join this webinar to learn strategies to shorten timelines while minimizing safety and regulatory risks for biologics development. The featured speaker will also detail CLD platform options and how testing across multiple platforms simultaneously can help reduce timelines and reduce risks.
Dr. Sufia Karim, Director, Cell Line Development, Aragen Life Sciences
Dr. Sufia Karim is Director of Cell Line Development & Late-Stage R&D at Aragen Bioscience, Inc. She has more than 18 years’ experience in the biotech industry, including leading cell line development, cell culture, process development & optimization, and successful tech transfer. Dr. Karim previously worked with Boehringer Ingelheim and Amgen. She earned her MD from Sir Salimullah Medical College (Dhaka, Bangladesh) and her MS in molecular and microbiology from San Jose State University.Message Presenter
Who Should Attend?
This webinar will be of interest to the following professionals working on biologics/biosimilars/biobetters:
- Research Scientist; Senior Scientist; Principal Scientist; Lead Scientist; Associate Director; Director level scientists
- VP, CMC; VP, R&D; CSO leading biologics/biosimilars/biobetters discovery and development programs
- Academic scientists
- Non-profit organization scientists
What You Will Learn
Join this webinar to learn:
- The strategies to shorten timelines while minimizing safety and regulatory risks for biologics development
- Cell line development (CLD) platform options and how testing across multiple platforms simultaneously can help reduce timelines and reduce risks
Aragen Bioscience, Inc. a subsidiary of Aragen Life Science, is focused on accelerating antibody and other biologic product development. Our integrated preclinical research offerings include: antibody discovery, recombinant protein production and purification, stable cell line development as well as cell-based assays and in vivo models-of-disease. Our team has been chosen for their scientific experience and diversity. We pride ourselves in our ability to understand each client’s unique needs, both, from a scientific as well as business perspective. This enables us to be not only a high-quality service provider, but also a preferred R&D partner. We’re located in the San Francisco Bay Area, California.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.Create Account